We asked respondents responsible for sterile injectable manufacturing outsourcing about the amount and type of outsourced compounds they have in development, in marketing, or foresee themselves having in five years. Overall, respondents anticipate having one additional small molecule sterile injectable product on the market in the next five years. Rates were on par for marketed biologic products, which are also predicted to increase by one product over the next five years.
View Resource